US drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly ...

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Pfizer here.

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

A Harvard Business School Healthcare Alumni Association Q&A with Dr. Henry A. McKinnell, former Chairman and CEO of Pfizer.

Pfizer CEO Dr. Albert Bourla joined “GMA3: What You Need To Know” Monday to discuss the drug-maker's coronavirus vaccine after early analysis shows it to be 90% effective at preventing COVID-19.

Pfizer CEO Dr. Albert Bourla joins William Brangham to discuss what comes next. The drug company Pfizer announced Monday that early data indicates its COVID-19 vaccine could be highly effective.

Pfizer CEO Albert Bourla said Monday he hasn't taken the COVID-19 vaccine yet -- but only because he doesn't want to be seen as jumping the line.

Pfizer’s competitor, Moderna, has similarly shown nearly 95% protection from Covid-19 infection. In comparison, the flu vaccine is around 40% to 60% effective, depending on the year.